{"entity":{"id":"vorolanib","kind":"drug","name":"Vorolanib","aka":["CM082","Fuwei"],"tldr":"Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed.","summary":"Vorolanib (X-82, CM082) was developed by Betta Pharmaceuticals in Hangzhou, licensed from Tyrogenex. The NMPA approved it in June 2023 in combination with everolimus for advanced renal cell carcinoma in patients whose disease had progressed on a prior tyrosine kinase inhibitor, on the CONCEPT phase 3 trial, which compared the combination with everolimus alone. It is also in trials in lung cancer and, as an eye drop formulation, in retinal disease.","status":"approved","asOf":"2026-09-16","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Vorolanib"},{"label":"ClinicalTrials.gov: trials of vorolanib","url":"https://clinicaltrials.gov/search?intr=vorolanib"}],"tags":["china","nmpa-approved"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["vegf"],"drugs":[],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo China deep dive","editedOn":"2026-09-16"},"code":"X-82","modality":"Oral multi-target VEGFR and PDGFR tyrosine kinase inhibitor","mechanism":"Blocks the VEGF and PDGF receptors that build and stabilise tumour blood vessels; designed as a shorter-acting relative of sunitinib to limit off-target toxicity.","approvals":[{"region":"CN","year":2023,"indication":"Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vorolanib/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"}]}}